Bharat Parenterals Ltd
Bharat Parenterals Q3 FY26: Revenue ₹65.2 Cr, Net loss ₹9.6 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹65Cr
- −9.8% YoY
- Net profit
- −₹10Cr
- Q3 FY25: −₹8 Cr
- Margin
- 2.67%
- −2.4 pp YoY
Guidance rank: #10 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Bharat Parenterals Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY26 Revenue from Operations (Consolidated): ₹65.2 crore, down 10% YoY from ₹72.3 crore in Q3 FY25 (Page 9). EBITDA for Q3 FY26 (Consolidated): ₹1.8 crore, down 52% YoY from ₹3.7 crore in Q3 FY25; margin at 3% vs. 5% YoY.
From Bharat Parenterals Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY26 Revenue from Operations (Consolidated): ₹65.2 crore, down 10% YoY from ₹72.3 crore in Q3 FY25 (Page 9).
- Q3 FY26 Standalone Revenue from Operations: ₹41.4 crore, down 39% YoY from ₹67.3 crore in Q3 FY25 (Page 5).
- Innoxel revenue guidance for full year FY26: ₹60–65 crore, contingent on milestone timing (Page 34).
- Varenyam Healthcare full-year revenue target for FY26: approx. ₹60 crore (Page 34).
2 more points from Bharat Parenterals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Bharat Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Innoxel Lifesciences: Capex ~₹250 crore; facility fully constructed, USFDA inspected, undergoing product validation (Page 19).
- Varenyam Bio Lifesciences: Capex ~₹30 crore till date; facility under construction with targeted operational readiness by FY27 (Page 19).
- Standalone (BPL): FY25 Capex ₹14+ crore (Page 18).
- Beta-Lactam Block upgrades: Civil and layout modifications completed to align with EU-GMP compliance; new water system installed (Page 6).
- General Injectable Vial Line upgraded to ORABS standards enhancing manufacturing efficiency (Page 6).
2 more points from Bharat Parenterals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bharat Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The presentation reports a robust order book of ₹303 crore, expected to benefit FY27 significantly, particularly in the first half (Page 34).
- Management notes a timing shift in institutional execution leading to a deferral of Purchase Orders (POs), impacting full-year FY26 revenue guidance but expects recovery in Q4FY26 (Page 34).
Bharat Parenterals Ltd — Quarterly revenue & net profit
Bharat Parenterals Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 65 | 72 | -9.8% | 65 | +0.9% |
| Operating profit (EBITDA) | 2 | 4 | -52.2% | 1 | +109.6% |
| Operating margin | 2.67% | 5.04% | -2.4 pp | 1.28% | +1.4 pp |
| Profit before tax | -8 | -6 | — | -7 | — |
| Net profit (PAT) | -10 | -8 | — | -9 | — |
| EPS (₹) | -6.37 | -2.42 | — | -10.49 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹100 Cr, net loss ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bharat Parenterals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Bharat Parenterals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Bharat Parenterals Ltd Q3 FY26 results?
Q3 FY26 Revenue from Operations (Consolidated): ₹65.2 crore, down 10% YoY from ₹72.3 crore in Q3 FY25 (Page 9). EBITDA for Q3 FY26 (Consolidated): ₹1.8 crore, down 52% YoY from ₹3.7 crore in Q3 FY25; margin at 3% vs. 5% YoY.
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,040 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
Innoxel Lifesciences: Capex ~₹250 crore; facility fully constructed, USFDA inspected, undergoing product validation (Page 19).
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.